1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market : Launch of Novel Oral Therapies to Result in Major Market Changes

  • November 2014
  • 65 pages
  • Frost & Sullivan
Report ID: 2506816


Table of Contents

Scope and Methodology

•This research service evaluates the market for prescription drugs and biologics for the long-term treatment of rheumatoid arthritis (RA) prescribed in addition to standard of care. It does not evaluate the market for corticosteroids, non-steroidal anti-inflammatory agents (NSAIDs), and other analgesics or background disease-modifying antirheumatic drug (DMARD) therapy.
•The study takes into account products in the market as well as those in development and discusses market challenges, drivers, and restraints. Segmentation by drug class is also provided along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
•The information provided in the research service has been derived from primary research with key opinion leaders and secondary research from published sources including disease control organization websites, public health organization websites, company publications including annual reports, SEC filings and press releases, government sources, and published articles in scientific journals.

Key Findings

•The number of people globally with RA is x million in 2014. The chronic disease is more prevalent in elderly patients.
•The overall disease prevalence is not expected to change significantly in the near term with the expected rise in the number of patients being x million in the next four years.
•The tumor necrosis factor (TNF) inhibitors Enbrel, Humira, and Remicade dominate the market as first-line standards of care.
•The TNF inhibitors are well entrenched and are expected to continue to dominate the market during 2015 and 2016, until the launch of new drug classes for the treatment of RA.
•New biologics arriving in the market will impact TNF inhibitors’ share. However, novel orals and biologics are generally reserved for anti-TNF refractory patients.
•High costs make biologics inaccessible to many patients, resulting in a need for less costly options without sacrificing safety or efficacy. Biosimilars, such as infliximab, which were launched in emerging markets, are expected to be the choice of many patients who are not able to purchase biologics.
•There are 11 marketed products globally, and 14 are in Phase III clinical trials. The research and development (R&D) trend is to develop TNF, interleukin, and Janus kinase (JAK) inhibitors, as well as Anti-Cluster of Differentiation (CD) products. R&D is focused on increasing efficacy and safety as well as lifestyle quality by changing the administration forms from subcutaneous to oral.
•Three products are expected to be launched in the United States in 2016.
•Bariticinib, developed by Eli Lilly, is an oral medication which causes fewer side effects than Pfizer’s tofacitinib, Xeljanz.
•BCD-020, developed by Biocad, is expected to make a major impact in the market for being the first anti-CD20 biosimilar approved for RA.
•SAR153191/REGN88, developed by Sanofi and Regeneron, is the first fully human monoclonal antibody anti-IL-6.

CEO’s Perspective

Rheumatoid arthritis is a highly complex disease, pharmacological management of which is challenging.
The market is dominated by three entrenched biologic products—Embrel, Humira, and Remicade.
The high cost of biologics limits patient access and leaves a large portion of the market untapped.
Changes in clinical practice trends, such as earlier diagnosis and early initiation of treatment, could expand the market.
In the light of availability of several safe and effective therapies, the bar for the approval of new therapies has been significantly raised.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024

  • $ 22000
  • Industry report
  • April 2017
  • by Datamonitor Healthcare

Introduction Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic ...

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • April 2017
  • by GlobalData

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025 Summary Cystic fibrosis (CF), which has been given a the diagnostic code E84 from The International Classification of Diseases, ...

NASH: KOL Insight [2017]

  • $ 9015
  • Industry report
  • June 2017
  • by Firstword Pharma

Will novel therapies revolutionise the treatment of NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five ...

Car-t Disease Outlook [2017]

June 2017 $ 8355


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.